Boston Life Sciences' Anti-Angiogenic Troponin is Shown in Animal Studies to Inhibit Retinal Angiogenesis.BOSTON--(BUSINESS WIRE)--July 14, 1998--Boston Life Sciences, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BLSI BLSI Boston Life Sciences, Inc. ) announced that in animal studies, BLSI's anti-angiogenic product Troponin I appeared to inhibit blood vessel formation in an animal eye model of retinal neovascularization. Prior animal studies had also indicated that Troponin troponin /tro·po·nin/ (tro´po-nin) a complex of muscle proteins which, when combined with Ca2+, influence tropomyosin to initiate contraction. tro·po·nin n. inhibited metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. tumor growth. A single intra-ocular injection of Troponin significantly (p<0.0005) inhibited retinal angiogenesis in this model. "In addition to our gratifying grat·i·fy tr.v. grat·i·fied, grat·i·fy·ing, grat·i·fies 1. To please or satisfy: His achievement gratified his father. See Synonyms at please. 2. results in the treatment of cancer, we are pleased to have received further evidence of Troponin's potent anti-angiogenic activity in an additional model of angiogensis", stated Marc Lanser, MD, Chief Scientific Officer of BLSI. "We consider these results highly encouraging since we did not optimize either dosing or delivery of Troponin to the retina in these experiments. Therefore in addition to development for cancer applications, we hope to move forward as rapidly as possible with the development of Troponin for the potential treatment of Macular Degeneration and Diabetic Retinopathy, two important angiogenic eye diseases affecting millions of individuals. Discussions with potential corporate partners to co-develop these and potentially other ophthalmic indications are ongoing, although no specific agreements have yet been reached," said Dr. Lanser. BLSI is developing novel treatments for cancer, autoimmune disease, and central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . In addition to Troponin I, a naturally-occuring anti-angiogenesis factor for the potential treatment of solid tumors and eye diseases, products under FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review, in clinical trials or in preclinical development by BLSI include THERAFECTIN for the treatment of Rheumatoid Arthritis; AF1 for the potential treatment of stroke and spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. ; Altropane, a radioimaging agent for the diagnosis of Parkinson's Disease and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies. The foregoing contains certain forward-looking statements with regard to product development timelines and corporate partnering discussions, which may not be realized due to the uncertainties inherent in the research and development and negotiating processes.
CONTACT: MARTIN E. JANIS & CO., Chicago
Bev Jedynak, 312/943-1100
or
Marc E. Lanser, MD
Chief Scientific Officer
617/425-0200
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion